Clough Capital Partners L P Crispr Therapeutics Ag Transaction History

Clough Capital Partners L P

$924 Million
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $1.07 Million - $1.43 Million	20,939 New	20,939 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $201,828 - $377,212	5,226 New	5,226 $327,000
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $2.83 Million - $4.41 Million	-65,131 Reduced 53.34%	56,969 $3.2 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $5.72 Million - $7.83 Million	-139,600 Reduced 53.34%	122,100 $5.52 Million
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $6 Million - $10.1 Million	-153,067 Reduced 36.9%	261,700 $10.6 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $5.96 Million - $8.17 Million	97,500 Added 30.73%	414,767 $27.1 Million
Q2 2022 Aug 16, 2022	BUY	$43.23 - $73.83 $4.81 Million - $8.21 Million	111,160 Added 53.93%	317,267 $19.3 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $5.32 Million - $7.93 Million	100,100 Added 94.43%	206,107 $12.9 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $2.47 Million - $3.93 Million	-35,300 Reduced 24.98%	106,007 $8.03 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $3.51 Million - $4.99 Million	-31,860 Reduced 18.4%	141,307 $15.8 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $1.39 Million - $2.24 Million	-13,810 Reduced 7.39%	173,167 $28 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $4.65 Million - $8.82 Million	41,970 Added 28.94%	186,977 $22.8 Million
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $9.71 Million - $21.1 Million	-121,820 Reduced 45.66%	145,007 $22.2 Million
Q3 2020 Nov 17, 2020	SELL	$78.5 - $100.64 $2.37 Million - $3.04 Million	-30,200 Reduced 10.17%	266,827 $22.3 Million
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $4.98 Million - $9.25 Million	-147,900 Reduced 33.24%	297,027 $12.6 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $1.28 Million - $2.55 Million	-34,876 Reduced 7.27%	444,927 $27.1 Million
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $1.58 Million - $2.02 Million	38,500 Added 8.72%	479,803 $19.7 Million
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $4.93 Million - $6.7 Million	-138,963 Reduced 23.95%	441,303 $20.8 Million
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $1.8 Million - $2.62 Million	64,200 Added 12.44%	580,266 $20.7 Million
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $4.05 Million - $7.55 Million	178,335 Added 52.8%	516,066 $14.7 Million
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $2 Million - $2.96 Million	-45,100 Reduced 11.78%	337,731 $15 Million
Q2 2018 Aug 14, 2018	SELL	$42.62 - $73.59 $7.56 Million - $13.1 Million	-177,400 Reduced 31.67%	382,831 $22.5 Million
Q1 2018 May 15, 2018	SELL	$23.52 - $58.17 $7.77 Million - $19.2 Million	-330,400 Reduced 37.1%	560,231 $25.6 Million
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $1.88 Million - $2.6 Million	110,700 Added 14.19%	890,631 $20.9 Million
Q3 2017 Nov 14, 2017	BUY	$16.75 - $20.66 $13.1 Million - $16.1 Million	779,931	779,931 $13.9 Million

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

Capital International Investors Los Angeles, CA

7.93M
Shares

$328 Million
0.07% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

7.5M
Shares

$311 Million
3.35% of portfolio
State Street Corp Boston, MA

2.99M
Shares

$124 Million
0.01% of portfolio
Sumitomo Mitsui Trust Holdings, Inc.

2.97M
Shares

$123 Million
0.1% of portfolio
Nikko Asset Management Americas, Inc.

2.97M
Shares

$123 Million
1.61% of portfolio

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

News

Stay updated on Clough Capital Partners L P with notifications on news.

Account